Bezuclastinib

Name: Bezuclastinib in Nonadvanced systemic mastocytosis: Pharmacodynamics
Published: 2026-09-14T15:39:06-04:00

Nonadvanced systemic mastocytosis

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the second half of 2026
Last updated: September 17, 2026

Section

Product information and disease description Product description Product information Pharmacology

Pharmacodynamics

1 evidence topic · 2 sources

Nonclinical central nervous system exposure

“Minimal brain exposure with no evidence of CNS-related effects in nonclinical safety pharmacology and toxicology studies” (opens the source at this quote in a new tab)